Prostate specific antigen gene regulation by androgen receptor

Journal of Cellular Biochemistry

Volumn 93, Issue 2, 2004, Pages 233-241

  Kim, Joshua ^a   Coetzee, Gerhard A ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Androgen receptor; Gene regulation; Prostate cancer; PSA; Transcription

Indexed keywords

ANDROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR; ANDROGEN;

ADVANCED CANCER; ARTICLE; GENE CONTROL; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TUMOR GROWTH; CHEMISTRY; CHROMATIN; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PROSTATE TUMOR; REVIEW;

ANDROGENS; CHROMATIN; GENE EXPRESSION REGULATION; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 16544369846     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20228     Document Type: Article

References (45)

1. Balk S. 2002. Androgen receptor as a target in androgen-independent prostate cancer. Urology 60:132-138.
2. Balk SP, Ko YJ, Bubley GJ. 2003. Biology of prostate-specific antigen. J Clin Oncol 21:383-391.
3. Buchanan G, Irvine RA, Coetzee GA, Tilley WD. 2001. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 20:207-223.
4. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. 1998. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 279:563-566.
5. Chen T, Wang LH, Farrar WL. 2000. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 60:2132-2135.
6. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. 1999. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 38:199-207.
7. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J. 1996. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 271:6379-6388.
8. Cohen P, Peehl DM, Graves HC, Rosenfeld RG. 1994. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 142:407-415.
9. Cramer SD, Chang BL, Rao A, Hawkins GA, Zheng SL, Wade WN, Cooke RT, Thomas LN, Bleecker ER, Catalona WJ, Sterling DA, Meyers DA, Ohar J, Xu J. 2003. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst 95:1044-1053.
10. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. 1994. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478.
11. Debes JD, Schmidt LJ, Huang H, Tindall DJ. 2002. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 62:5632-5636.
12. Denmeade SR, Isaacs JT. 2002. A history of prostate cancer treatment. Nat Rev Cancer 2:389-396.
13. Diamandis EP, Yousef GM. 2001. Human tissue kallikrein gene family: A rich source of novel disease biomarkers. Expert Rev Mol Diagn 1:182-190.
14. Feldman BJ, Feldman D. 2001. The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45.
15. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J, Hunt DF, Weber MJ. 2002. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 277:29304-29314.
16. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, Wilson EM. 2004. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 279:7119-7130.
17. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z. 2001. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 7:2941-2948.
18. Huang W, Shostak Y, Tarr P, Sawyers C, Carey M. 1999. Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J Biol Chem 274:25756-25768.
19. Jia L, Kim J, Shen H, Clark PE, Tilley WD, Coetzee GA. 2003. Androgen receptor activity at the prostate specific antigen locus: Steroidal and non-steroidal mechanisms. Mol Cancer Res 1:385-392.
20. Jia L, Choong CS, Ricciardelli C, Kim J, Tilley WD, Coetzee GA. 2004. Androgen receptor signaling: Mechanism of interleukin-6 inhibition. Cancer Res 64:2619-2626.
21. Johnstone RW. 2002. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287-299.
22. Kim J, Jia L, Tilley WD, Coetzee GA. 2003. Dynamic methylation of histone H3 at lysine 4 in transcriptional regulation by the androgen receptor. Nucleic Acids Res 31:6741-6747.
23. Kozlowski JM, Ellis WJ, Grayhack JT. 1991. Advanced prostatic carcinoma. Early versus late endocrine therapy. Urol Clin North Am 18:15-24.
24. Lin DL, Whitney MC, Yao Z, Keller ET. 2001. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res 7:1773-1781.
25. Louie MC, Yang HQ, Ma AH, Xu W, Zou JX, Kung HJ, Chen HW. 2003. Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex. Proc Natl Acad Sci USA 100:2226-2230.
26. Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Carvalho R, Lopes C. 2002. Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate 53:88-94.
27. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M. 2000. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6:2702-2706.
28. Nazareth LV, Weigel NL. 1996. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 271:19900-19907.
29. Orio F, Jr., Terouanne B, Georget V, Lumbroso S, Avances C, Siatka C, Sultan C. 2002. Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines. Mol Cell Endocrinol 198:105-114.
30. Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM, Tilley WD, Stallcup MR, Press MF, Coetzee GA. 2000. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res 60:5946-5949.
31. Rahman M, Miyamoto H, Chang C. 2004. Androgen receptor coregulators in prostate cancer: Mechanisms and clinical implications. Clin Cancer Res 10:2208-2219.
32. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman J. 1991. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 5:1921-1930.
33. Rosenfeld MG, Glass CK. 2001. Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 276:36865-36868.
34. Sadar MD, Hussain M, Bruchovsky N. 1999. Prostate cancer: Molecular biology of early progression to androgen independence. Endocr Relat Cancer 6:487-502.
35. Santos-Rosa H, Schneider R, Bannister AJ, Sherriff J, Bernstein BE, Emre NC, Schreiber SL, Mellor J, Kouzarides T. 2002. Active genes are tri-methylated at K4 of histone H3. Nature 419:407-411.
36. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. 1991. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 51:222-226.
37. Strahl BD, Allis CD. 2000. The language of covalent histone modifications. Nature 403:41-45.
38. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. 1995. Interleukin-6: A candidate mediator of human prostate cancer morbidity. Urology 45:542-549.
39. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. 2002. Ligand-independent activation of the androgen receptor by IL-6 and the role of the coactivator SRC-1 in prostate cancer cells. J Biol Chem 277:38087-38094.
40. Weber MJ, Gioeli D. 2004. Ras signaling in prostate cancer progression. J Cell Biochem 91:13-25.
41. Xu J, Meyers DA, Sterling DA, Zheng SL, Catalona WJ, Cramer SD, Bleecker ER, Ohar J. 2002. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. Cancer Epidemiol Biomarkers Prev 11:664-669.
42. Xue W, Irvine RA, Yu MC, Ross RK, Coetzee GA, Ingles SA. 2000. Susceptibility to prostate cancer: Interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 60:839-841.
43. Xue WM, Coetzee GA, Ross RK, Irvine R, Kolonel L, Henderson BE, Ingles SA. 2001. Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort. Cancer Epidemiol Biomarkers Prev 10:575-579.
44. Yang L, Wang L, Lin HK, Kan PY, Xie S, Tsai MY, Wang PH, Chen YT, Chang C. 2003. Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun 305:462-469.
45. Zhang Y, Reinberg D. 2001. Transcription regulation by histone methylation: Interplay between different covalent modifications of the core histone tails. Genes Dev 15:2343-2360.